Balwinder Singh
Balwinder Singh is an expert in Psychiatry at Mayo Clinic (United States, Rochester) (United States). As of October 2026, ScienceLeadR ranks Balwinder Singh in the top 1% of experts worldwide for Mood Disorders and Depressive Disorder. Balwinder Singh has authored 475 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 4 of them ongoing. SLR score: 1,729 (community average: 125). How the SLR is computed.
LeadR Profile
Psychiatry
Subspecialties: Pharmacy - Neurology - Cardiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2011 - 2026
Number : 475
Citations
Main journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| GLP-1 Receptor Agonists and Risk of Kidney Replacement Therapy and Health Care Utilization in Bipolar Disorder With Chronic Kidney Disease. PMID 42848524 — kidney diseases, glucagon-like peptide 1, bipolar disorder, glucagon-like peptide-1 receptor, kidney, dipeptidyl-peptidase iv inhibitors, obesity, sex, therapeutics, patient acceptance of health care, renal replacement therapy, psychiatry | J Clin Psychiatry | 2026 | 0 |
| Modulation of GABA and glutamate by ketamine in depression: A systematic review and meta-analysis of magnetic resonance spectroscopy studies. PMID 42768091 — depression, brain, ketamine, therapeutics | Neuropsychopharmacology | 2026 | 0 |
| SGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort study. PMID 42632571 — kidney diseases, glucagon-like peptide 1, sodium-glucose transporter 2 inhibitors, bipolar disorder, mortality, glucagon-like peptide-1 receptor, hospitalization, cohort studies, kidney, therapeutics, affective symptoms, renal replacement therapy | J Affect Disord | 2026 | 0 |
| Metabolomic correlates of intravenous racemic ketamine in treatment-resistant major depressive disorder: the Bio-K/NNDC multicenter trial. PMID 42702010 — antidepressive agents, biological psychiatry, ketamine, depressive disorder, metabolomics, therapeutics, hydrocortisone, depressive disorder, major | World J Biol Psychiatry | 2026 | 0 |
| GLP-1 Receptor Agonists, Lithium, and the Kidneys: A Tale of Two Signals. PMID 42690023 — glucagon-like peptide 1, glucagon-like peptide-1 receptor, kidney, psychopharmacology | J Clin Psychopharmacol | 2026 | 0 |
Clinical Studies 8
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B cell Non Hodgkin Lymphoma Before CAR T cell Therapy NCT06834373 — ligases, cells, lymphoma, follicular, ubiquitin, bone marrow, blood, hodgkin disease, lymphoma, b-cell, pharmaceutical preparations, tomography, lymphoma, germinal center, lymphoma, large b-cell, diffuse, positron-emission tomography, neoplasms, blood component removal, leukapheresis, biopsy, positron emission tomography computed tomography, immunotherapy, rituximab, receptors, antigen, leukocytes, receptors, chimeric antigen, antibodies, monoclonal, immunotherapy, adoptive, specimen handling, lymphoma, non-hodgkin, blood cells, therapeutics, ubiquitin-protein ligases, histiocytes, t-lymphocytes, b-lymphocytes, receptors, antigen, t-cell, biosimilar pharmaceuticals, car-t cell, bone and bones | Phase 2 | Recruiting | 2025 |
| Intravenous Ketamine for Treatment Resistant Depression NCT06668571 — depression, saline solution, ketamine, solutions, depressive disorder, body weight, therapeutics, depressive disorder, treatment-resistant, depressive disorder, major | Phase 2 | Recruiting | 2025 |
| Understanding the Mechanisms of Clonal and Non clonal Cytopenia Following CAR T Therapy for Multiple Myeloma or CD19 Lymphoproliferative Disorder (LPD) NCT06630104 — cells, research design, genes, genetic testing, bone marrow, blood, follow-up studies, chromatin immunoprecipitation sequencing, neoplasms, chromatin immunoprecipitation, chromatin, electronic health records, genetic counseling, signs and symptoms, multiple myeloma, immunoprecipitation, specimen handling, records, therapeutics, lymphoproliferative disorders, counseling, receptors, antigen, t-cell, cytopenia, bone and bones | N/A | Recruiting | 2024 |
| Evaluating the Association Among Changes in Gut Microbiome Fatigue and Chemotherapy Induced Nausea in Early Stage Breast Cancer NCT05417867 — blood, breast neoplasms, neoplasms, drug therapy, vomiting, fatigue, breast, nausea, specimen handling, gastrointestinal microbiome, chemotherapy, carcinoma | N/A | Recruiting | 2021 |
LeadR Networks
Main global connection map